Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of December 2020. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital and voting rights.
- Issued Share Capital (as of 30 November 2020): 5,385,136,645 Ordinary Shares of 25 pence each.
- Treasury Shares: 367,705,950 Ordinary Shares.
- Total Voting Rights: 5,017,430,695.
Material Changes
The filing does not disclose material changes in financial performance or operations compared to prior periods. It provides a static snapshot of the share capital and voting rights as of 30 November 2020.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. Its sole purpose is to establish the denominator for shareholder notification calculations under FCA rules.
Key Facts for Investor Verification
- Verify the total number of voting rights (5,017,430,695) to determine if disclosure thresholds for shareholding interests have been met.
- Confirm the number of shares held in Treasury (367,705,950) which are excluded from the voting rights count.
- Note that this filing does not contain financial results; investors should refer to Form 20-F or quarterly reports for financial metrics.